F. Furlaneto

Universidade de São Paulo

Health Outcomes Studied

• Increased Anti-Inflammatory Cytokine Levels
• Reduced Interleukin-6 Levels
• Reduced Tumor Necrosis Factor Alpha

Papers (9)

• 2023
  Bifidobacterium animalis subspecies lactis HN019 can reduce the sequelae of experimental periodontitis in rats modulating intestinal parameters, expression of lipogenic genes, and levels of hepatic steatosis.10.1111/jre.13163
• 2022
  Probiotic consumption can modify the resilience of periodontal tissues in rats under experimental periodontitis.10.1002/JPER.21-0555
• 2022
  Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases10.3390/ijms23169334
• 2021
  The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: an immunoenzymatic and microtomographic study.10.1002/JPER.21-0285
• 2020
  Effects of Bifidobacterium animalis subsp. lactis HN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis.10.3920/bm2019.0038
• 2020
  Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients10.1371/journal.pone.0238425
• 2018
  Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial10.1111/jcpe.12995
• 2017
  Benefits of Bifidobacterium animalis subsp. lactis Probiotic in Experimental Periodontitis10.1902/jop.2016.160217
• 2017
  Effects of the probiotic Bifidobacterium animalis subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats10.1371/journal.pone.0179946